Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997893 · ClinicalTrials.gov registry record · Phase 2
Research Investigation of Soy and Estrogen
A Phase 2 study of Menopause and Hot Flashes, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT00997893 is a Phase 2 study of Menopause and Hot Flashes that has completed, run by University of Illinois at Chicago. The registered enrollment target is 96 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00997893, a Phase 2 study of Menopause and Hot Flashes, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.
Conditions Studied
Interventions
- DRUG Estradiol
- DIETARY_SUPPLEMENT Soy Phytoestrogen
- DRUG Medroxyprogesterone Acetate (MPA)
- DRUG Soy Placebo
- DRUG MPA Placebo
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997893
The ClinicalTrials.gov registry entry for NCT00997893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 5 interventions - of which Estradiol is the first listed.
NCT00997893 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00997893 about?
NCT00997893 is a clinical study titled "Research Investigation of Soy and Estrogen". The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.
What is the current status of trial NCT00997893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2009-12. Estimated completion is 2015-05.
What conditions does trial NCT00997893 study?
This clinical trial studies the following conditions: Menopause, Hot Flashes.
What interventions are being tested in trial NCT00997893?
The interventions under investigation include: Estradiol (DRUG), Soy Phytoestrogen (DIETARY_SUPPLEMENT), Medroxyprogesterone Acetate (MPA) (DRUG), Soy Placebo (DRUG), MPA Placebo (DRUG).
Who is sponsoring clinical trial NCT00997893?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00997893 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
Impact of Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.